Mark Leonard Singleton Sells 6,498 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the sale, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The stock was sold at an average price of $10.53, for a total value of $113,018.49.

Bioventus Stock Up 0.6 %

Shares of NYSE BVS opened at $10.01 on Friday. The stock has a market capitalization of $812.36 million, a PE ratio of -16.41 and a beta of 0.85. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The firm has a fifty day moving average of $10.32 and a 200-day moving average of $10.85. Bioventus Inc. has a 52-week low of $3.90 and a 52-week high of $14.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in Bioventus during the 4th quarter worth approximately $38,000. Virtus Fund Advisers LLC purchased a new position in Bioventus in the third quarter valued at approximately $42,000. Quest Partners LLC acquired a new position in Bioventus during the third quarter valued at approximately $51,000. Finally, Quarry LP acquired a new position in Bioventus during the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analyst Weigh In

BVS has been the topic of several recent analyst reports. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.